λΌλ―ΈλΆλ
**λΌλ―ΈλΆλ (Lamivudine)**(λλ **3TC**)μ μμνμμ μ£Όλ‘ **κ³ μμ΄ λ©΄μκ²°ν λ°μ΄λ¬μ€(FIV)** κ΄λ¦¬μ μ¬μ©λλ νλ°μ΄λ¬μ€μ μ λλ€. 무μ¦μ κ³ μμ΄μ κ²½μ° μμ μ¦μ λ°νμ μ§μ°μν¬ μ μμ΅λλ€. μ¦μμ΄ μλ κ³ μμ΄μ κ²½μ° ν볡μ λκΈ° μν΄ λ³μ© μλ²μ μΌλΆλ‘ μμ£Ό μ¬μ©λ©λλ€. > **μμ κ²½κ³ :** λΌλ―ΈλΆλμ 골μ μ΅μ λ₯Ό μ λ°ν μ μμΌλ―λ‘ μ κΈ°μ μΈ νμ‘νμ λͺ¨λν°λ§μ΄ νμμ μ λλ€. **μμ ν:** λΌλ―ΈλΆλμ μ§λλΆλ(Zidovudine)κ³Ό λ³μ©νλ©΄ μ§λλΆλ λ¨λ μλ²λ³΄λ€ λ°μ΄λ¬μ€ μμ μ€μ΄κ³ CD4/CD8 λΉμ¨μ κ°μ νλ λ° λ ν¨κ³Όμ μΈ κ²μΌλ‘ λνλ¬μ΅λλ€.
μμ© κΈ°μ : Lamivudine is a **nucleoside reverse transcriptase inhibitor (NRTI)**. It acts as an analogue of cytidine. Once phosphorylated to its active triphosphate form intracellularly, it competes with natural substrates and incorporates into viral DNA. This causes **chain termination** β inhibits the **viral reverse transcriptase** enzyme β prevents viral replication.
λλ¬Ό μ’ λ³ μ©λ
- Treatment of FIV-positive cats Β· 25 mg/kg Β· PO Β· q12h Β· May be combined with zidovudine for enhanced efficacy.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Anaemia
- Pre-existing severe bone marrow suppression
μ΄μλ°μ
- Cytopenias (predicted)
- Anaemia
- Leukopenia
μ½λ¬Ό μνΈμμ©
- Zidovudine Β· Synergistic therapeutic effect; more effective at reducing viral load and increasing CD4/CD8 ratios than zidovudine alone.
λͺ¨λν°λ§
- Complete Blood Count (CBC) regularly to monitor for cytopenias
- CD4/CD8 ratios
- Viral load
κ³Όμ©λ
Information on overdosage in veterinary species is limited. Overdose is likely to exacerbate hematological toxicities such as **severe cytopenias** (anemia, leukopenia). Treatment should be supportive and symptomatic.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.